Publication: Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
2
Issued Date
2021-01-01
Resource Type
ISSN
17474094
17474086
17474086
Other identifier(s)
2-s2.0-85111685589
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Hematology. Vol.14, No.7 (2021), 633-644
Suggested Citation
John Porter, Ali Taher, Vip Viprakasit, Antonis Kattamis, Thomas D. Coates, Maciej Garbowski, Franz Dürrenberger, Vania Manolova, Frank Richard, M. Domenica Cappellini Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Expert Review of Hematology. Vol.14, No.7 (2021), 633-644. doi:10.1080/17474086.2021.1935854 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78671
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
Abstract
Introduction: In β-thalassemia, imbalanced globin synthesis causes reduced red blood cell survival and ineffective erythropoiesis. Suppressed hepcidin levels increase ferroportin-mediated iron transport in enterocytes, causing increased iron absorption and potentially iron overload. Low hepcidin also stimulates ferroportin-mediated iron release from macrophages, increasing transferrin saturation (TSAT), potentially forming non-transferrin-bound iron, which can be toxic. Modulating the hepcidin–ferroportin axis is an attractive strategy to improve ineffective erythropoiesis and limit the potential tissue damage resulting from iron overload. There are no oral β-thalassemia treatments that consistently ameliorate anemia and prevent iron overload. Areas covered: The preclinical and clinical development of vamifeport (VIT-2763), a novel ferroportin inhibitor, was reviewed. PubMed, EMBASE and ClinicalTrials.gov were searched using the search term ‘VIT-2763ʹ. Expert opinion: Vamifeport is the first oral ferroportin inhibitor in clinical development. In healthy volunteers, vamifeport had comparable safety to placebo, was well tolerated and rapidly decreased iron levels and reduced TSAT, consistent with observations in preclinical models. Data from ongoing/planned Phase II studies are critical to define its potential in β-thalassemia and other conditions associated with iron overabsorption and/or ineffective erythropoiesis. If vamifeport potentially increases hemoglobin and reduces iron-related parameters, it could be a suitable treatment for non-transfusion-dependent and transfusion-dependent β-thalassemia.